Proposal for a Two-Tier Re-classification of Stage IV/M1 domain of Renal Cell Carcinoma into M1 (“Oligometastatic”) and M2 (“Polymetastatic”) subdomains: Analysis of the Registry for Metastatic Renal Cell Carcinoma (REMARCC)
Margaret Meagher(University of California San Diego), Ithaar Derweesh(Rush University Medical Center), Franklin Liu(University of California San Diego), Eduard Roussel, Vital Hevia(Hospital Universitario Ramón y Cajal), Maria Carmen Mir(Fundación Instituto Valenciano de Oncología), Tobias Klatte(Helios Hospital Bad Saarow), Enrico Checcucci(University of Turin), Francesco Porpiglia(University of Turin), Estefanía Linares(Hospital Universitario La Paz), Matthias Heck(TUM Klinikum), M. D’Anna(Hospital Clínic de Barcelona), Michele Marchioni(University of Chieti-Pescara), Riccardo Campi(University of Florence), Riccardo Autorino(Rush University Medical Center), Thomas Amiel(Technical University of Munich), Maximilian C. Kriegmair(University Medical Centre Mannheim), José Rubio(Fundación Instituto Valenciano de Oncología), Georgi Guruli(VCU Massey Comprehensive Cancer Center), Rana R. McKay(University of California San Diego), Siska Van Bruwaene(AZ Groeninge), Jonathan Afari(University of California San Diego), Cesare Saitta(University of California San Diego), Mireía Musquera(Surgical Specialties (Canada)), Alessandro Antonelli(University of Verona), Nicola Pavan(Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo), Francesco Claps(University of Trieste), Alessandro Veccia(University of Verona), Maarten Albersen, Andrea Mari(Azienda Ospedaliero-Universitaria Careggi), Andrea Minervini(University of Florence), Carlotta Palumbo(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”)
Cited by 8
Related Papers
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
RETRACTED ARTICLE: Microbiome analyses of blood and tissues suggest cancerdiagnostic approach
|Nature|2020|1k
Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2023|592
NCCN Guidelines Insights: Prostate Cancer, Version 1.2021
|Journal of the National Comprehensive Cancer Network|2021|532
Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer
|European Urology|2014|297